Characterization of acute heart failure hospitalizations in a Portuguese cardiology department

Ana Catarina Pinho-Gomes\textsuperscript{a}, José Silva Cardoso\textsuperscript{a, b, c, *}, Luís Filipe Azevedo\textsuperscript{b}, Rui Almeida\textsuperscript{c}, Teresa Pinho\textsuperscript{c}, Maria Júlia Maciel\textsuperscript{c}

\textsuperscript{a} Department of Cardiology, Faculty of Medicine, University of Porto, Porto, Portugal
\textsuperscript{b} Department of Health Information and Decision Sciences (CIDES) and Centre for Research in Health Technologies and Information Systems (CINTESIS), Faculty of Medicine, University of Porto, Porto, Portugal
\textsuperscript{c} Department of Cardiology, Hospital de S. João, Porto, Portugal

Received 8 September 2012; accepted 31 October 2012
Available online 16 July 2013

Abstract

Introduction and Aims: We describe the clinical characteristics, management and outcomes of patients hospitalized with acute heart failure in a south-west European cardiology department. We sought to identify the determinants of length of stay and heart failure rehospitalization or death during a 12-month follow-up period.

Methods and Results: This was a retrospective cohort study including all patients admitted during 2010 with a primary or secondary diagnosis of acute heart failure. Death and readmission were followed through 2011.

Of the 924 patients admitted, 201 (21%) had acute heart failure, 107 (53%) of whom had new-onset acute heart failure. The main precipitating factors were acute coronary syndrome (63%) and arrhythmia (14%). The most frequent clinical presentations were heart failure after acute coronary syndrome (63%), chronic decompensated heart failure (47%) and acute pulmonary edema (21%). On admission 73% had left ventricular ejection fraction <50%. Median length of stay was 11 days and in-hospital mortality was 5.5%. The rehospitalization rate was 21% and 24% at six and 12 months, respectively. All-cause mortality was 16% at 12 months. The independent predictors of rehospitalization or death were heart failure hospitalization during the previous year (Hazard ratio − HR − 3.177), serum sodium <135 mmol/l on admission (HR 1.995) and atrial fibrillation (HR 1.791). Reduced left ventricular ejection fraction was associated with a lower risk of rehospitalization or death (HR 0.518).

Conclusions: Our patients more often presented new-onset acute heart failure, due to an acute coronary syndrome, with reduced left ventricular ejection fraction. Several predictive factors of death or rehospitalization were identified that may help to select high-risk patients to be followed in a heart failure management program after discharge.

© 2012 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L. All rights reserved.

* Corresponding author.
E-mail address: silvacardoso30@gmail.com (J. Silva Cardoso).

0870-2551/S - see front matter © 2012 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L. All rights reserved.
http://dx.doi.org/10.1016/j.repc.2012.10.018
Caracterização das hospitalizações por insuficiência cardíaca aguda num serviço de cardiologia português

Resumo
Introdução e objetivos: Dada a escassa informação relativa aos internamentos por insuficiência cardíaca aguda em serviços de Cardiologia portugueses, procedemos à sua caracterização. Pretendemos identificar os determinantes de maior duração de internamento e de rehospitalização ou morte aos 12 meses.
Métodos e resultados: Realizámos um estudo de cohort retrospetivo, incluindo os doentes admitidos em 2010 com diagnóstico primário ou secundário de insuficiência cardíaca aguda. A ocorrência de morte ou rehospitalização foi acompanhada durante 2011.
Do total de 924 hospitalizações, 201 (21%) apresentavam insuficiência cardíaca aguda, sendo o primeiro episódio em 107 (53%) das mesmas. Os principais fatores precipitantes foram síndrome coronária aguda (63%) e arritmia (14%). As apresentações clínicas mais comuns foram insuficiência cardíaca no contexto de síndrome coronária aguda (63%), insuficiência cardíaca crónica descompensada (46%) e edema pulmonar agudo (21%). Na admissão, 73% tinham fração de ejeção ventricular esquerda < 0,50. A duração mediana de internamento foi 11 dias e a mortalidade intra-hospitalar foi 5,5%. A taxa de rehospitalização aos 6 e 12 meses foi 21% e 24%, respetivamente. A mortalidade por todas as causas, aos 12 meses, foi 16%. Os factores preditores de rehospitalização ou morte foram hospitalização por insuficiência cardíaca aguda no ano anterior (Hazard ratio – HR – 3,177), sódio sérico < 135 mEq/L na admissão (HR 1,995), fibrilhacão auricular (HR 1,791). Fraccão de ejeccão ventricular esquerda deprimida na admissão associou-se a menor risco de rehospitalização ou morte (HR 0,518).
Conclusões: Os nossos doentes apresentavam mais frequentemente insuficiência cardíaca aguda de novo, com fração de ejeccão ventricular esquerda deprimida, no contexto de síndrome coronária aguda. Os vários factores preditores de mortalidade ou rehospitalização identificados poderão contribuir para selecionar os doentes de alto risco que justificam acompanhamento especializado numa clínica de insuficiência cardíaca.

Introduction

Acute heart failure (AHF) is a major public health concern because of its increasing prevalence and associated high morbidity, mortality and costs.1-5 Despite being one of the most frequent reasons for hospitalization in western countries, it has received much less attention than chronic heart failure (CHF), and large-scale studies specifically addressing AHF are relatively scarce.6,7 AHF is associated with a high rate of rehospitalization but little is known regarding the most relevant predictive factors. It is therefore important to develop appropriate predictive models that might help to appropriately stratify AHF patients and improve their management and follow-up.8

Moreover, although several studies have been conducted in Europe and the USA on the clinical characteristics, treatment and outcome of AHF patients, little information is available on this subject in Portugal.9

In the present study we describe the clinical characteristics, hospital management and outcomes of AHF patients admitted to a Portuguese cardiology department, and present a predictive model for readmission or death at 12 months in this population.

Objectives

The primary objective of this study was to describe the clinical characteristics, hospital management and outcomes of patients hospitalized with AHF.

The secondary objectives were:

- to compare patients with AHF and acute coronary syndrome (ACS) as the precipitating factor vs. patients with AHF and no ACS;
- to compare drug prescriptions on admission and at discharge;
- to identify factors associated with longer hospital length of stay (LOS);
- to identify risk factors for heart failure (HF) rehospitalization or death.

Methods

Study description

This was a hospital-based observational retrospective cohort study, conducted at the Cardiology Department of Hospital de S. João, Porto, Portugal. Demographic, clinical and follow-up data were collected between February 1, 2011 and December 31, 2011, ensuring a minimum follow-up of one year for all patients.

Inclusion criteria

All patients admitted to the cardiology department between January 1 and December 31, 2010 were screened. Paper-based and computerized clinical records on the 924 patients
The study was carried out according to the principles of the Declaration of Helsinki and was approved by the hospital’s ethics committee.
Results

Baseline characteristics

Of a total of 924 patients admitted to the cardiology department over a period of one year, 201 (21%) presenting with AHF were enrolled. Patients’ baseline characteristics are summarized in Tables 1 and 2. New-onset AHF occurred in more than 50% of cases. Hypertension and coronary heart disease (CHD) were the most prevalent underlying diseases, but all the cardiovascular risk factors were relatively frequent. The most common precipitating factor was ACS (63.3% of patients), followed by arrhythmia (14.4% of patients). The most frequent clinical presentation by far was HF in the context of ACS, followed by chronic decompensated heart failure (CDHF) and pulmonary edema. Interestingly, pulmonary edema was approximately twice as common in patients presenting with ACS than in those with no ACS, while CDHF was approximately three times more frequent in those without ACS than in those with. The majority of patients had reduced LVEF on admission.

Patients presenting with ACS were significantly younger, more often women and less likely to have a history of HF; they more often had chronic hypertension and CHD. On the other hand, patients without ACS more frequently had valvular disease and dilated cardiomyopathy, left...
ventricular hypertrophy pattern on the ECG, larger left atrial diameter and AF.

Hospital course and management

Echocardiographic examination and BNP measurement were performed in most patients and the majority were admitted to the ICCU and underwent coronary angiography. Overall use of in-hospital resources was similar in both ACS and non-ACS groups (Table 3), although a higher proportion of ACS patients were admitted to the ICCU. Non-invasive ventilation, intravenous nitrates and diuretics were the basis of therapy and the first two were more often used in ACS patients.

Discharge characteristics

Comparing admission with discharge, we observed a significant drop in body weight (median $-3$ kg [p25–p75: $-6-0$]; p<0.001), systolic blood pressure (mean $-17.1$ mmHg; SD 29.7; p<0.001), heart rate (mean $-18.7$ bpm; SD 32.4; p<0.001) and BNP (median $-203.5$ pg/dl [p25–p75: $-850.5-74.9$]; p<0.001). There was no improvement in creatinine clearance, serum sodium and potassium, or serum hemoglobin. The rate of prescription of all cardiovascular drugs increased from admission to discharge, apart from digoxin and calcium channel blockers (Figure 1).

Hospital stay and follow-up

Total LOS was similar in the two groups (median 11 days). In-hospital mortality was 5.5% and was not significantly different between the two groups. The rate of rehospitalization for HF was 20.9% and 23.9% at six and 12 months, respectively. Most readmissions occurred within six weeks after the index event. All-cause mortality was 10.9% and 15.9% at six and 12 months, respectively. The variables independently associated with a longer LOS were history of HF hospitalization in the previous year (p=0.040), BNP >500 pg/ml (p<0.001) on admission and ICCU admission (p=0.002) (Table 1 in Supplementary Material).

The most important variables predictive of the combined endpoint of rehospitalization or death during follow-up were history of HF hospitalization in the previous year (hazard ratio [HR] 3.177 [1.405–7.185]), serum sodium <135 mmol/l on admission (HR 1.995 [1.032–3.856]) and AF (HR 1.791 [1.021–3.142]). Reduced LVEF (HR 0.518 [0.268–0.998]) was associated with a lower risk of rehospitalization or death (Table 2 in Supplementary Material).
Table 3 Diagnostic investigations, procedures and acute cardiac care.

<table>
<thead>
<tr>
<th>Procedure/treatment (% performed)</th>
<th>All patients (n=201)</th>
<th>Patients with ACS (n=127)</th>
<th>Patients without ACS (n=74)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Admission to ICCU</td>
<td>77.1</td>
<td>91.3</td>
<td>52.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ECG</td>
<td>98.5</td>
<td>100.0</td>
<td>95.9</td>
<td>0.049</td>
</tr>
<tr>
<td>Echocardiography</td>
<td>96.5</td>
<td>98.4</td>
<td>93.2</td>
<td>0.103</td>
</tr>
<tr>
<td>BNP</td>
<td>89.6</td>
<td>91.3</td>
<td>86.5</td>
<td>0.340</td>
</tr>
<tr>
<td>Cardiac scintigraphy</td>
<td>10.4</td>
<td>13.4</td>
<td>5.4</td>
<td>0.074</td>
</tr>
<tr>
<td>Coronary angiography</td>
<td>69.7</td>
<td>85.3</td>
<td>45.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Pulmonary artery catheter</td>
<td>5.5</td>
<td>4.7</td>
<td>6.8</td>
<td>0.188</td>
</tr>
<tr>
<td>Percutaneous coronary intervention</td>
<td>32.8</td>
<td>48.8</td>
<td>5.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Invasive ventilation</td>
<td>8.5</td>
<td>8.7</td>
<td>8.1</td>
<td>0.892</td>
</tr>
<tr>
<td>Non-invasive ventilation</td>
<td>63.5</td>
<td>69.3</td>
<td>53.4</td>
<td>0.025</td>
</tr>
<tr>
<td>Intravenous diuretics</td>
<td>62.5</td>
<td>58.3</td>
<td>59.9</td>
<td>0.103</td>
</tr>
<tr>
<td>Intravenous nitrates</td>
<td>34.5</td>
<td>42.5</td>
<td>20.5</td>
<td>0.002</td>
</tr>
<tr>
<td>Intravenous inotropes</td>
<td>13.9</td>
<td>13.4</td>
<td>14.9</td>
<td>0.770</td>
</tr>
<tr>
<td>Intra-aortic balloon pump</td>
<td>3.5</td>
<td>5.5</td>
<td>0.0</td>
<td>0.048</td>
</tr>
<tr>
<td>Dialysis</td>
<td>2.5</td>
<td>2.4</td>
<td>2.7</td>
<td>1.000</td>
</tr>
<tr>
<td>Pacemaker</td>
<td>5.0</td>
<td>1.6</td>
<td>10.8</td>
<td>0.004</td>
</tr>
<tr>
<td>ICD</td>
<td>6.5</td>
<td>4.7</td>
<td>9.5</td>
<td>0.188</td>
</tr>
</tbody>
</table>

*p value for difference between patients presenting with or without ACS. ACS, acute coronary syndrome; BNP, B-type natriuretic peptide; ICCU, intensive cardiac care unit; ICD, implantable cardioverter/defibrillator.

Discussion

Hospitalizations due to AHF are associated with high mortality and readmission rates, and represent about 70% of all costs associated with HF. They typically occur in internal medicine or cardiology departments and thus most studies include a mixed population from both provenances.

Clinical information provided by hospital-based studies is crucial to our understanding of the contemporary clinical characteristics of AHF, including key prognostic factors and details regarding clinical presentation and medical therapy. We therefore conducted a hospital-based observational retrospective study in order to identify the particular characteristics of AHF patients admitted exclusively to a cardiology department.

Demographics, underlying diseases, type of onset, precipitating factors and clinical presentation of acute heart failure

In our study, the mean age and gender distribution of patients were similar to those of previous AHF registries in Europe and elsewhere and in the USA. However, our patients were younger and more often male than those included in an earlier Portuguese study performed in

Figure 1 Oral medication on admission and at discharge for acute heart failure patients. McNemar test for related samples. ACE: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; BB: beta-adrenergic receptor blocker; CCB: calcium channel blocker; MRA: mineralocorticoid receptor antagonist.
Characterization of acute heart failure hospitalizations

internal medicine wards. Unlike in many previous reports, the majority of our patients had reduced LV function, which was perhaps a consequence of the high prevalence of ACS in our population. Interestingly, a recent Italian study also showed that patients admitted to cardiology departments were younger, more often male and more likely to have reduced LVEF than patients in internal medicine wards, which is in agreement with our findings but not with the aforementioned Portuguese study.

Cardiovascular disease was common among our patients, most frequently CHD and hypertension, as observed in previous international surveys. Conventional cardiovascular risk factors, such as obesity, diabetes and dyslipidemia, were also very frequent. The prevalence of noncardiovascular comorbidities was similar to that observed in previous surveys. Chronic pulmonary diseases, anemia and kidney disease were common, with mean creatinine clearance compatible with grade 3 renal failure. This was similar to that observed in ADHERE, highlighting the importance of heart-kidney interaction in AHF.

Most patients had new-onset HF, particularly those with an ACS as precipitating factor. The prevalence of new-onset AHF was much higher than in EHFSII and ALARM-HF. ACS was the precipitating factor in nearly two-thirds of patients. This was almost twice the figure observed in reports that included patients of mixed provenance (from internal medicine and cardiology departments). Arrhythmias were the second most frequent precipitating factor and were more common in the non-ACS group. They were mostly of supraventricular origin, which is in line with previous reports of the high frequency of AF among AHF patients.

As in EHFSII and ALARM-HF, two of the most common clinical presentations of AHF in our population were CDHF and pulmonary edema.

Diagnostic investigations and treatment

ECG, BNP measurement and echocardiographic examination were performed in nearly all patients on admission or within the first days of hospitalization, showing good adherence to the European Society of Cardiology (ESC) HF guidelines. The high prevalence of ACS explains why coronary angiography was performed in more than two-thirds of our patients and why a considerably higher percentage of them were admitted to the ICU, compared to EHFSII.

As previously reported by others, ventilatory support and intravenous diuretic therapy played a central role in acute management. Non-invasive ventilation was used in the majority of patients. The frequency of administration of intravenous nitrates was similar to that in previous surveys, while the use of inotropes was nearly half. Approximately one-third of the patients presented with ST-segment elevation myocardial infarction and underwent percutaneous coronary intervention. This was considerably more frequent than in ADHERE and EHFSII.

The observed decrease in body weight, heart rate and BNP at discharge reflected clinical improvement with therapy. Interestingly, blood pressure fell, but no improvement in serum creatinine value was observed, which demonstrates the limitations of current therapeutic options regarding renal function.

The prescription of drugs recommended for HF, CHD and hypertension increased significantly from admission to discharge. However, the proportion of patients taking angiotensin converting-enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) was lower than in EHFSII; a possible explanation for this may be the proportion of our patients (26.8%) with HF and preserved LVEF, for which these drugs are not formally indicated. By contrast, the levels of prescription of beta-blockers, statins, aspirin, clopidogrel and nitrates at discharge exceeded that of EHFSII, possibly because ACS was more frequent in our study than in that survey and these drugs are recommended for secondary prophylaxis of ACS.

Length of stay, outcomes and follow-up of acute heart failure patients (Table 4)

The overall LOS was 11 days, two days longer than in EHFSII and ALARM-HF and almost three times that reported in ADHERE. The median ICU stay was six days, twice that reported in EHFSII and ALARM-HF. However, in our case, in-hospital mortality was 5.5%, which was lower than in EHFSII (6.6%) and ALARM-HF (12%). The large-scale US surveys ADHERE and OPTIMIZE-HF reported in-hospital mortality of nearly 4%, which is even lower than ours. Nonetheless, this low in-hospital mortality, which may in part have been a consequence of the very short LOS, was counterbalanced by higher readmission rate and long-term mortality (for instance, OPTIMIZE-HF reported 90-day readmission rates and mortality of 30% and 35%, respectively). It is possible that longer hospital stay could enable better patient stabilization, reducing long-term morbidity and mortality.

Our results reinforce the notion that AHF hospitalizations are associated with poor prognosis, with more than one-third of patients dying or being rehospitalized over the subsequent year.

Our patients with new-onset AHF had a more severe clinical presentation, which is consistent with ALARM-HF. However, in the long run patients with CDHF had a higher risk of rehospitalization or death.

The probability of being rehospitalized was highest during the first weeks after discharge from the index event, which attests the need of an early medical appointment after discharge, preferably in the setting of a particular HF management program.

Predictive factors of longer hospitalization and adverse outcome

The predictive factors for rehospitalization after an AHF event are largely unexplored in the literature. In our study a baseline BNP value higher than 500 pg/ml was the most important factor associated with longer LOS, followed by admission to the ICU, both indicating a more severe initial clinical picture. History of HF hospitalizations in the previous year, a recognized marker of bad prognosis, was also associated with longer hospital stay and with a threefold increase in the risk of dying or being rehospitalized during the year after discharge. AF also showed a significant
Patients with vs. without acute coronary syndrome as the precipitating factor

Patients with an ACS typically presented left atrial dilatation, preserved left ventricular dimensions and reduced LVEF on admission. Left atrial dilatation was possibly a consequence of history of hypertension observed in more than 70% of patients. On the contrary, in the early days of new-onset AHF due to an ACS, the left ventricle would not have had sufficient time to undergo eccentric remodeling.

Patients with ACS had more frequent and longer ICCU admissions and were more often treated with non-invasive ventilation and intra-aortic balloon pump than those without ACS. This suggests they have a worse initial clinical course. Nonetheless, there was no difference between groups in total hospital LOS, readmission rate, in-hospital mortality or mortality at six or 12 months.

Study limitations

An inherent limitation of this study derives from its retrospective nature. An additional drawback is the possibility that death or rehospitalization occurring out of our institution during follow-up were not reported. This could partly explain the observed low long-term rehospitalization and death rates. However, the consistency in the referral of patients indicates that this was probably not a major problem, and moreover cannot explain the low rates of in-hospital mortality also found in our study.

Conclusion

Patients admitted to our cardiology department with AHF more typically presented new-onset AHF, in the context of an ACS, causing deterioration in LV systolic function. They had longer LOS but lower 12-month readmission rate and mortality than reported in US and European studies. Independent predictors of rehospitalization or death were HF hospitalization during the previous year, serum sodium <135 mmol/l on admission and AF. Reduced LVEF was associated with a decreased risk of rehospitalization or death.

Table 4 Length of stay, outcomes and follow-up.

<table>
<thead>
<tr>
<th>Length of stay (days), median [p25-p75]</th>
<th>All patients (n=201)</th>
<th>Patients with ACS (n=127)</th>
<th>Patients without ACS (n=74)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>11 [7-16]</td>
<td>11 [7-16]</td>
<td>11 [6-18]</td>
<td>0.864</td>
</tr>
<tr>
<td>ICU</td>
<td>6 [4;12]</td>
<td>3 [2;5]</td>
<td>1 [0;4]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cardiology ward</td>
<td>6 [4;12]</td>
<td>6 [4;11]</td>
<td>7 [4;14]</td>
<td>0.131</td>
</tr>
<tr>
<td>In-hospital mortality (%)</td>
<td>5.5</td>
<td>3.9</td>
<td>8.1</td>
<td>0.210</td>
</tr>
<tr>
<td>Follow-up</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospitalization within 6 months (%)</td>
<td>20.9</td>
<td>18.9</td>
<td>24.3</td>
<td>0.361</td>
</tr>
<tr>
<td>Hospitalization within 12 months (%)</td>
<td>23.9</td>
<td>22.8</td>
<td>25.7</td>
<td>0.649</td>
</tr>
<tr>
<td>Department of first readmission (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiology department</td>
<td>27.1</td>
<td>24.1</td>
<td>31.6</td>
<td></td>
</tr>
<tr>
<td>Internal medicine department</td>
<td>66.7</td>
<td>69.0</td>
<td>63.2</td>
<td>0.843</td>
</tr>
<tr>
<td>ICU of emergency department</td>
<td>6.3</td>
<td>6.9</td>
<td>5.3</td>
<td></td>
</tr>
<tr>
<td>Months after index admission, median [p25-p75]</td>
<td>1.5 [0.8-4.5]</td>
<td>2.0 [1.0-5.0]</td>
<td>1.5 [0.5-4.0]</td>
<td>0.586</td>
</tr>
<tr>
<td>Mortality at six months (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart failure</td>
<td>7.5</td>
<td>4.7</td>
<td>12.2</td>
<td>0.053</td>
</tr>
<tr>
<td>All-cause</td>
<td>10.9</td>
<td>8.7</td>
<td>14.9</td>
<td>0.174</td>
</tr>
<tr>
<td>Mortality at 12 months (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart failure</td>
<td>10.9</td>
<td>8.7</td>
<td>14.9</td>
<td>0.174</td>
</tr>
<tr>
<td>All-cause</td>
<td>15.9</td>
<td>14.2</td>
<td>18.9</td>
<td>0.375</td>
</tr>
<tr>
<td>Adverse endpointb</td>
<td>34.8</td>
<td>31.5</td>
<td>40.5</td>
<td>0.301</td>
</tr>
</tbody>
</table>

a Number of heart failure rehospitalizations during the year after index admission.

b Adverse endpoint defined as death or heart failure rehospitalization during the total follow-up period. p value for difference between patients presenting with or without ACS. ICCU: intensive cardiac care unit; ICU: intensive care unit.
Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data and that all the patients included in the study received sufficient information and gave their written informed consent to participate in the study.

Right to privacy and informed consent. The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.

Conflicts of interest

The authors have no conflicts of interest to declare.

Appendix A. Supplementary material

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.repcc.2012.10.018.

References